189 related articles for article (PubMed ID: 23787099)
21. Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening.
Elkamhawy A; Ammar UM; Paik S; Abdellattif MH; Elsherbeny MH; Lee K; Roh EJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500757
[TBL] [Abstract][Full Text] [Related]
22. Discovery of novel pyruvate dehydrogenase kinases inhibitors by screening of an in-house small molecule library for anti-lung cancer therapeutics.
Guo F; Zhao S; Li X
Bioorg Med Chem Lett; 2019 Jan; 29(2):291-296. PubMed ID: 30470491
[TBL] [Abstract][Full Text] [Related]
23. Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches.
Meganathan C; Sakkiah S; Lee Y; Narayanan JV; Lee KW
J Mol Model; 2013 Feb; 19(2):715-26. PubMed ID: 23015102
[TBL] [Abstract][Full Text] [Related]
24. An iterative compound screening contest method for identifying target protein inhibitors using the tyrosine-protein kinase Yes.
Chiba S; Ishida T; Ikeda K; Mochizuki M; Teramoto R; Taguchi YH; Iwadate M; Umeyama H; Ramakrishnan C; Thangakani AM; Velmurugan D; Gromiha MM; Okuno T; Kato K; Minami S; Chikenji G; Suzuki SD; Yanagisawa K; Shin WH; Kihara D; Yamamoto KZ; Moriwaki Y; Yasuo N; Yoshino R; Zozulya S; Borysko P; Stavniichuk R; Honma T; Hirokawa T; Akiyama Y; Sekijima M
Sci Rep; 2017 Sep; 7(1):12038. PubMed ID: 28931921
[TBL] [Abstract][Full Text] [Related]
25. Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway.
Němec V; Hylsová M; Maier L; Flegel J; Sievers S; Ziegler S; Schröder M; Berger BT; Chaikuad A; Valčíková B; Uldrijan S; Drápela S; Souček K; Waldmann H; Knapp S; Paruch K
Angew Chem Int Ed Engl; 2019 Jan; 58(4):1062-1066. PubMed ID: 30569600
[TBL] [Abstract][Full Text] [Related]
26. YES1: A Novel Therapeutic Target and Biomarker in Cancer.
Garmendia I; Redin E; Montuenga LM; Calvo A
Mol Cancer Ther; 2022 Sep; 21(9):1371-1380. PubMed ID: 35732509
[TBL] [Abstract][Full Text] [Related]
27. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
[No Abstract] [Full Text] [Related]
28. Probing 2H-Indazoles as Templates for SGK1, Tie2, and SRC Kinase Inhibitors.
Schoene J; Gazzi T; Lindemann P; Christmann M; Volkamer A; Nazaré M
ChemMedChem; 2019 Aug; 14(16):1514-1527. PubMed ID: 31264364
[TBL] [Abstract][Full Text] [Related]
29. Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation.
Mishra RK; Alokam R; Singhal SM; Srivathsav G; Sriram D; Kaushik-Basu N; Manvar D; Yogeeswari P
J Chem Inf Model; 2014 Oct; 54(10):2876-86. PubMed ID: 25254429
[TBL] [Abstract][Full Text] [Related]
30. An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2.
Meirson T; Samson AO; Gil-Henn H
Drug Des Devel Ther; 2017; 11():1535-1557. PubMed ID: 28572720
[TBL] [Abstract][Full Text] [Related]
31. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
[TBL] [Abstract][Full Text] [Related]
32. De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.
Urich R; Wishart G; Kiczun M; Richters A; Tidten-Luksch N; Rauh D; Sherborne B; Wyatt PG; Brenk R
ACS Chem Biol; 2013 May; 8(5):1044-52. PubMed ID: 23534475
[TBL] [Abstract][Full Text] [Related]
33. Small molecule inhibitors of IκB kinase β: A chip-based screening and molecular docking simulation.
Cho YW; Lim HJ; Han MH; Kim BC; Han S
Bioorg Med Chem; 2020 May; 28(9):115440. PubMed ID: 32205046
[TBL] [Abstract][Full Text] [Related]
34. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
[TBL] [Abstract][Full Text] [Related]
35. Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.
Lawrence HR; Mahajan K; Luo Y; Zhang D; Tindall N; Huseyin M; Gevariya H; Kazi S; Ozcan S; Mahajan NP; Lawrence NJ
J Med Chem; 2015 Mar; 58(6):2746-63. PubMed ID: 25699576
[TBL] [Abstract][Full Text] [Related]
36. SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
Sato H; Kubota D; Qiao H; Jungbluth A; Rekhtman N; Schoenfeld AJ; Yu HA; Riely GJ; Toyooka S; Lovly CM; Paik P; Ladanyi M; Fan PD
JCO Precis Oncol; 2022 Aug; 6():e2200088. PubMed ID: 35952318
[TBL] [Abstract][Full Text] [Related]
37. Identification of new Fyn kinase inhibitors using a FLAP-based approach.
Poli G; Tuccinardi T; Rizzolio F; Caligiuri I; Botta L; Granchi C; Ortore G; Minutolo F; Schenone S; Martinelli A
J Chem Inf Model; 2013 Oct; 53(10):2538-47. PubMed ID: 24001328
[TBL] [Abstract][Full Text] [Related]
38. Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.
Kook E; Chun KS; Kim DH
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338729
[TBL] [Abstract][Full Text] [Related]
39. Discovery of novel CK2 leads by cross-docking based virtual screening.
Sun H; Wu X; Xu X; Jiang Z; Liu Z; You Q
Med Chem; 2014; 10(6):628-39. PubMed ID: 24286395
[TBL] [Abstract][Full Text] [Related]
40. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
